These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28905734)

  • 1. Swift and Certain, Proportionate and Consistent: Key Values of Urine Drug Test Consequences for Probationers.
    Cadwallader AB
    AMA J Ethics; 2017 Sep; 19(9):931-938. PubMed ID: 28905734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy.
    Morasco BJ; Krebs EE; Cavanagh R; Hyde S; Crain A; Dobscha SK
    J Opioid Manag; 2015; 11(1):45-51. PubMed ID: 25750164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):124-31. PubMed ID: 22104461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results.
    Turner JA; Saunders K; Shortreed SM; Rapp SE; Thielke S; LeResche L; Riddell KM; Von Korff M
    J Gen Intern Med; 2014 Feb; 29(2):305-11. PubMed ID: 24142119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of drugs in Australian prisons: supply reduction strategies.
    Dolan K; Rodas A
    Int J Prison Health; 2014; 10(2):111-7. PubMed ID: 25764074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urine testing in the treatment of opiate addiction].
    Ege PP
    Ugeskr Laeger; 2003 Mar; 165(13):1346-8. PubMed ID: 12703279
    [No Abstract]   [Full Text] [Related]  

  • 7. Urine drug testing in chronic pain.
    Christo PJ; Manchikanti L; Ruan X; Bottros M; Hansen H; Solanki DR; Jordan AE; Colson J
    Pain Physician; 2011; 14(2):123-43. PubMed ID: 21412368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory-Generated Urine Toxicology Interpretations: A Mixed Methods Study.
    Chua IS; Ransohoff JR; Ehrlich O; Katznelson E; Virk ZM; Demetriou CA; Petrides AK; Orav EJ; Schiff GD; Melanson SEF
    Pain Physician; 2021 Mar; 24(2):E191-E201. PubMed ID: 33740356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choosing the right laboratory: a review of clinical and forensic toxicology services for urine drug testing in pain management.
    Reisfield GM; Goldberger BA; Bertholf RL
    J Opioid Manag; 2015; 11(1):37-44. PubMed ID: 25750163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using urine drug testing to support healthy boundaries in clinical care.
    Heit HA; Gourlay DL
    J Opioid Manag; 2015; 11(1):7-12. PubMed ID: 25750160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic pain.
    Setnik B; Roland CL; Pixton GC; Sommerville KW
    Postgrad Med; 2017 Jan; 129(1):5-11. PubMed ID: 27782769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine drug testing: current recommendations and best practices.
    Owen GT; Burton AW; Schade CM; Passik S
    Pain Physician; 2012 Jul; 15(3 Suppl):ES119-33. PubMed ID: 22786451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation of urine drug testing in pain patients.
    Pesce A; West C; Egan City K; Strickland J
    Pain Med; 2012 Jul; 13(7):868-85. PubMed ID: 22494459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic.
    Pytell JD; Rastegar DA
    J Subst Abuse Treat; 2021 Jan; 120():108155. PubMed ID: 33298297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Affecting Drug Use During Incarceration: A Cross-Sectional Study of Opioid-Dependent Persons from India.
    Rao R; Mandal P; Gupta R; Ramshankar P; Mishra A; Ambekar A; Jhanjee S; Dhawan A
    J Subst Abuse Treat; 2016 Feb; 61():13-7. PubMed ID: 26470597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine Spiking in a Pain Medicine Clinic: An Attempt to Simulate Adherence.
    Lee D; Bazydlo LA; Reisfield GM; Goldberger BA
    Pain Med; 2015 Jul; 16(7):1449-51. PubMed ID: 25522892
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of reported drug use and urinalysis in the assessment of drug use.
    Jain R; Tripathi BM; Singh R
    Natl Med J India; 2001; 14(5):315-6. PubMed ID: 11767230
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of urine drug testing for patients on opioid therapy.
    Pergolizzi J; Pappagallo M; Stauffer J; Gharibo C; Fortner N; De Jesus MN; Brennan MJ; Richmond C; Hussey D;
    Pain Pract; 2010; 10(6):497-507. PubMed ID: 20412503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.